PapersFlow Research Brief
Coronary Interventions and Diagnostics
Research Guide
What is Coronary Interventions and Diagnostics?
Coronary interventions and diagnostics encompass procedures and techniques used to diagnose and treat coronary artery disease, including percutaneous coronary intervention (PCI), stenting, angioplasty, and physiological assessments like fractional flow reserve (FFR) to evaluate stenoses and guide revascularization.
The field has produced 104,822 works reflecting extensive research on managing coronary artery disease through guidelines, trials, and imaging advancements. Key guidelines such as "2018 ESC/EACTS Guidelines on myocardial revascularization" by Neumann et al. (2018) standardize revascularization strategies for myocardial ischemia. Landmark trials like "Optimal Medical Therapy with or without PCI for Stable Coronary Disease" by Boden et al. (2007) demonstrate that PCI added to optimal medical therapy does not reduce death or myocardial infarction risk in stable patients.
Research Sub-Topics
Drug-Eluting Stents
This sub-topic covers development of stents releasing antiproliferative drugs to prevent restenosis, including polymer coatings, drug release kinetics, and long-term safety profiles. Researchers compare first- vs. second-generation devices in diverse patient populations.
Fractional Flow Reserve
FFR-guided PCI studies assess hemodynamic significance of intermediate stenoses using pressure wires to improve revascularization decisions. Meta-analyses confirm ischemia-driven strategies reduce events vs. angiography alone.
Bifurcation Lesion Stenting
Researchers compare provisional vs. two-stent strategies for coronary bifurcations, optimizing techniques like culotte, DK-crush, and T-stenting. Dedicated bifurcation stents and imaging outcomes are also evaluated.
Intravascular Imaging in PCI
IVUS and OCT studies guide stent optimization by assessing underexpansion, malapposition, and edge dissections to minimize thrombosis risk. Comparative trials demonstrate reduced stent thrombosis with imaging guidance.
Transradial Coronary Intervention
Radial access research demonstrates reduced bleeding, vascular complications, and mortality vs. femoral approach, particularly in ACS. Studies optimize sheaths, hemostasis devices, and operator training.
Why It Matters
Coronary interventions and diagnostics directly influence patient outcomes in acute coronary syndromes and stable disease by enabling precise revascularization decisions. For instance, "Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials" by Keeley et al. (2003) showed primary angioplasty reduces mortality by 25% compared to thrombolysis across 23 trials involving thousands of patients. Guidelines like "2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation" by Collet et al. (2020) provide evidence-based protocols adopted worldwide, improving survival rates in non-ST-elevation myocardial infarction. Recent FDA Breakthrough Device Designations for AI tools, such as Powerful Medical's PMcardio STEMI AI ECG model (2025) and Prevencio's HART CADhs test (2025), enhance non-invasive detection of obstructive CAD, reducing reliance on invasive angiography in clinical practice.
Reading Guide
Where to Start
"2018 ESC/EACTS Guidelines on myocardial revascularization" by Neumann et al. (2018), as it provides a comprehensive, accessible framework for revascularization strategies in coronary disease, serving as an entry point before trial-specific papers.
Key Papers Explained
"Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)" by Norgren et al. (2007) establishes foundational management principles later adapted to coronary contexts. "Clinical End Points in Coronary Stent Trials" by Cutlip et al. (2007) standardizes outcomes used in trials like "Optimal Medical Therapy with or without PCI for Stable Coronary Disease" by Boden et al. (2007), which directly tests PCI versus medical therapy. Guidelines "2014 ESC/EACTS Guidelines on myocardial revascularization" by Windecker et al. (2014) and "2018 ESC/EACTS Guidelines on myocardial revascularization" by Neumann et al. (2018) iteratively refine these based on accumulating trial evidence.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent preprints focus on imaging-guided PCI, including ECLIPSE trial on intravascular imaging for calcified lesions (2025), FLAVOUR extended follow-up comparing FFR and IVUS (2025), and FAME 2 long-term FFR results (2026). AI advancements like Powerful Medical's FDA-designated PMcardio (2025) and Heartflow's diagnostic platform drive non-invasive frontiers.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Inter-Society Consensus for the Management of Peripheral Arter... | 2007 | Journal of Vascular Su... | 8.1K | ✓ |
| 2 | 2018 ESC/EACTS Guidelines on myocardial revascularization | 2018 | European Heart Journal | 6.8K | ✓ |
| 3 | Efficacy and safety of more intensive lowering of LDL choleste... | 2010 | The Lancet | 6.2K | ✓ |
| 4 | Clinical End Points in Coronary Stent Trials | 2007 | Circulation | 5.4K | ✕ |
| 5 | 2020 ESC Guidelines for the management of acute coronary syndr... | 2020 | European Heart Journal | 4.8K | ✓ |
| 6 | Optimal Medical Therapy with or without PCI for Stable Coronar... | 2007 | New England Journal of... | 4.6K | ✓ |
| 7 | A Comparison of Balloon-Expandable-Stent Implantation with Bal... | 1994 | New England Journal of... | 4.5K | ✓ |
| 8 | ACC/AHA Guidelines for the Management of Patients With Unstabl... | 2000 | Circulation | 4.5K | ✓ |
| 9 | Primary angioplasty versus intravenous thrombolytic therapy fo... | 2003 | The Lancet | 4.3K | ✕ |
| 10 | 2014 ESC/EACTS Guidelines on myocardial revascularization | 2014 | European Heart Journal | 4.3K | ✓ |
In the News
Powerful Medical Receives FDA Breakthrough Device ...
**Powerful Medical, a leader in AI-driven cardiovascular diagnostics, announces that its PMcardio STEMI AI ECG model has been granted Breakthrough Device Designation by the U.S. Food and Drug Admin...
Prevencio Receives FDA Breakthrough Device ...
**Breakthrough Device Designation** to its **HART CADhs® test**. This designation recognizes HART CADhs as an innovative technology for identifying **obstructive coronary artery disease (CAD)**—a c...
AI breakthrough in diagnosing heart disease
* As the leading cause of death in the US, coronary artery disease can now be assessed more quickly and accurately with Heartflow. * The AI platform achieves accuracy close to invasive methods and ...
HeartSciences Receives FDA Breakthrough Device ...
The algorithm was developed using advanced convolutional neural network (CNN) deep learning techniques and trained on more than 120,000 ECG records. In performance evaluations, it demonstrated the ...
Ultromics Lands $55M Series C to Tackle Undiagnosed ...
**Oxford, UK, July 31, 2025 - Ultromics **, a pioneer in AI-driven cardiology solutions, today announced it has raised $55 million in Series C financing. The round was co-led by L&G ,[Allegis
Code & Tools
* MONAI Core : A domain-specific framework for training AI models for healthcare imaging * MONAI Label : An intelligent image labeling and learning...
This repository provides the material necessary to run inference on a DICOM coronary angiography video of the algorithms constituting DeepCoro, des...
This is an implementation of "Deep Learning Prediction for Percutaneous Recanalization of Chronic Total Occlusion Using Coronary CT Angiography".
The jupyter notebook file contains preprocessing of images to get segments of arteries that might be helpful to build a system that has to explore ...
Recent Preprints
EuroIntervention | Your reference journal for coronary, valvular ...
This content covers a wide range of cardiology interventions, including coronary, valvular, heart failure, peripheral, hypertension, and stroke management procedures. Trending articles ### State-...
Fractional flow reserve-guided percutaneous coronary intervention versus medical therapy for stable coronary artery disease: long-term results of the FAME 2 trial
In patients with stable coronary artery disease (CAD), the long-term benefits of revascularization over medical therapy remain unclear. In the Fractional Flow Reserve versus Angiography for Multive...
Intravascular Imaging vs Angiography Guidance for PCI of Severely Calcified Lesions: The ECLIPSE Trial - PubMed
Display options FormatAbstractPubMedPMID ## Abstract **Background:**Few studies have examined whether intravascular imaging (IVI) guidance during percutaneous coronary intervention (PCI) of calcifi...
Long-Term Outcomes After Fractional Flow Reserve vs Intravascular Ultrasound to Guide PCI: The FLAVOUR Trial Extended Follow-Up - PubMed
**Background:**The optimal treatment strategy for patients with intermediate coronary stenosis remains uncertain. **Objectives:**The aim of this study was to investigate the long-term outcomes of a...
Fractional flow reserve vs angiography to guide... : European Heart Journal
Received February 18, 2025 Received in revised form March 26, 2025 Accepted June 25, 2025 This article is published and distributed under the terms of the Oxford University Press, Standard Journals...
Latest Developments
Recent developments in coronary interventions and diagnostics include the ECLIPSE trial comparing intravascular imaging versus angiography guidance for PCI of severely calcified lesions, published in October 2025, which suggests potential benefits of imaging-guided procedures (pubmed.ncbi.nlm.nih.gov) and a study indicating that intravascular imaging-guided stent optimization can reduce target vessel failure, especially in patients with ACS (JACC, JACC, as of May 2024). Additionally, long-term results of the FAME 2 trial published in January 2026 support the use of fractional flow reserve-guided PCI for stable coronary artery disease (nature.com). The upcoming EAPCI Summit 2026 also highlights ongoing advancements and research in interventional cardiology (escardio.org).
Sources
Frequently Asked Questions
What defines clinical end points in coronary stent trials?
Clinical end points in coronary stent trials include death, myocardial infarction, and target vessel revascularization, standardized by the Academic Research Consortium to reduce interpretation confusion. "Clinical End Points in Coronary Stent Trials" by Cutlip et al. (2007) established harmonized definitions and timing for safety and effectiveness assessments across trials.
How does PCI compare to medical therapy in stable coronary disease?
In stable coronary artery disease, PCI added to optimal medical therapy does not reduce the risk of death, myocardial infarction, or other major cardiovascular events. "Optimal Medical Therapy with or without PCI for Stable Coronary Disease" by Boden et al. (2007) from the COURAGE trial (NCT00007657) confirmed this in over 2,000 patients followed long-term.
What do ESC guidelines recommend for myocardial revascularization?
"2018 ESC/EACTS Guidelines on myocardial revascularization" by Neumann et al. (2018) recommend heart team approaches for revascularization decisions in chronic coronary syndromes, prioritizing guideline-directed medical therapy alongside PCI or surgery based on anatomy and symptoms. These guidelines update prior versions like the 2014 edition by Windecker et al.
What is the role of FFR in guiding PCI?
Fractional flow reserve (FFR ≤ 0.80) identifies hemodynamically significant stenoses to guide PCI in stable coronary artery disease. The FAME 2 trial, as in "Fractional flow reserve-guided percutaneous coronary intervention versus medical therapy for stable coronary artery disease: long-term results of the FAME 2 trial" (2026 preprint), evaluates long-term benefits of FFR-guided revascularization over medical therapy alone.
How do intravascular imaging and FFR compare for PCI guidance?
Trials like the FLAVOUR extended follow-up compare long-term outcomes of FFR-guided versus intravascular ultrasound (IVUS)-guided PCI strategies. "Long-Term Outcomes After Fractional Flow Reserve vs Intravascular Ultrasound to Guide PCI: The FLAVOUR Trial Extended Follow-Up" (2025 preprint) assesses target vessel failure rates in intermediate stenoses.
What are current applications of AI in coronary diagnostics?
AI tools like Powerful Medical's PMcardio STEMI AI ECG model and Heartflow's platform achieve accuracy near invasive methods for STEMI and CAD detection. FDA Breakthrough Device Designations in 2025 recognize these for faster, non-invasive assessment of coronary artery disease.
Open Research Questions
- ? What are the long-term clinical benefits of FFR-guided PCI versus medical therapy alone in stable coronary artery disease, as unresolved in FAME 2 extended results?
- ? Does intravascular imaging guidance improve outcomes over angiography alone in severely calcified coronary lesions, per the ECLIPSE trial?
- ? How do FFR and IVUS compare for long-term target vessel outcomes in intermediate stenoses, beyond FLAVOUR trial follow-up?
- ? Can AI models trained on ECGs or CT angiography reliably predict percutaneous recanalization success in chronic total occlusions?
- ? What thresholds optimize AI-driven diagnostics for obstructive CAD detection without invasive confirmation?
Recent Trends
FDA granted Breakthrough Device Designation to Powerful Medical's PMcardio STEMI AI ECG (March 2025), Prevencio's HART CADhs for obstructive CAD (May 2025), and HeartSciences' algorithm detecting aortic stenosis (June 2025), signaling AI integration in diagnostics.
Preprints emphasize FFR versus IVUS guidance, with FLAVOUR extended follow-up (August 2025) and ECLIPSE trial on calcified lesions (October 2025); field has 104,822 works.
Research Coronary Interventions and Diagnostics with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Coronary Interventions and Diagnostics with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.